3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
4
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
17
Carcinoma, Hepatocellular
5
Recurrence
4
Neoplasms, Plasma Cell
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Liver Neoplasms
3
Sarcoma
2
NSCLC
2
Lymphoma, Large B-Cell, Diffuse
2
Esophageal Neoplasms
2
Waldenstrom Macroglobulinemia
1
Stomach Neoplasms
1
Pathologic Complete Response
1
Osteosarcoma
1
Neoplasms, Second Primary
1
Neoplasms
1
Melanoma
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Large Granular Lymphocytic
1
Leiomyosarcoma
1
Kidney Neoplasms
1
Immunoglobulin Light-chain Amyloidosis
1
Immunoblastic Lymphadenopathy
1
Glioblastoma
1
Extrapancreatic Neuroendocrine Tumor
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Cyclophosphamide
9
Radiotherapy
5
Rituximab
4
Peripheral Blood Stem Cell Transplantation
4
Cyclosporine
4
fludarabine phosphate
3
Melphalan
3
Indium
3
Filgrastim
3
Dexamethasone
3
sargramostim
2
epratuzumab
2
Radioimmunodetection
2
Paclitaxel
2
Mycophenolic Acid
2
Metronidazole
2
Lym-1 monoclonal antibody
2
Lenalidomide
2
Interferon-alpha
2
Idarubicin
2
Etoposide
2
Cytarabine
2
Clarithromycin
2
Cisplatin
2
Busulfan
2
Antilymphocyte Serum
2
Amoxicillin
2
motesanib diphosphate
1
ledipasvir, sofosbuvir drug combination
1
ibritumomab tiuxetan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Lymphoma, B-Cell, Marginal Zone
×
Thalidomide
×
Clear all
NCT03335098
2017-11-07
BOMB-THROW
Seoul National University Hospital
Phase 2
Unknown
15 enrolled